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Toll-like receptors (TLRs) are not only crucial to the initiation of the immune system, but also play a key role in several human
inﬂammatory diseases. Hepatocellular carcinoma (HCC) is among those human cancers, which arise from sites of chronic
inﬂammation. Therefore, a number of studies have explored the potential contribution of TLRs to HCC occurrence, which
is initiated by exposure to chronic hepatic inﬂammation of diﬀerent etiologies (including ethanol, and chronic B and C viral
infections). Recent epidemiological data have shown the association of obesity and HCC development. Given the fact that adipose
tissuescanproduceavarietyofinﬂammation-relatedadipokines,obesityhasbeencharacterizedasastateofchronicinﬂammation.
Adipokinesarethereforeconsidered asimportantmediatorslinkinginﬂammationtoseveral metabolic diseases,includingcancers.
More recently, many experts have also shown the bridging role of TLRs between inﬂammation and metabolism. Hopefully, to
retrieve the potential interaction between TLRs and adipokines in carcinogenesis of HCC will shed a new light on the therapeutic
alternative for HCC. In this paper, the authors ﬁrst review the respective roles of TLRs and adipokines, discuss their mutual
interaction in chronic inﬂammation, and ﬁnally anticipate further investigations of this interaction in HCC development.
1. Overviewsof Toll-Like Receptors (TLRs)
Since Drosophila Toll was found to resemble the amino
acid sequence of the cytoplasmic portion of interleukin-
1 (IL-1), accumulated studies have unveiled the crucial
role of Toll-like receptors (TLRs) in induction of innate
immune responses [1, 2]. Host cells express a variety of
pattern recognition receptors (PRRs) that recognize diverse
pathogen-associated molecular patterns (PAMPs), including
lipids, lipoproteins, proteins, and nucleic acids [3, 4]. TLRs
belong to the family of type I transmembrane receptors
characterized by an extracellular leucine rich repeat (LRR)
domain that is responsible for recognition of PAMPs and an
intracellular domain homologous to the cytoplasmic region
of the IL-1 receptor (known as TIR domain) that is required
for downstream signaling [5, 6]. To date, at least eleven
members of human TLR family have been identiﬁed and
recognized diﬀerent PAMPs derived from distinct microor-
ganisms, including bacteria, viruses, protozoa, and fungi [7].
The TIR domain is required for the interaction and
recruitment of various adaptor molecules to activate diverse
downstream signaling pathways. Several TIR domain-
containing adaptor molecules have been deﬁned, includ-
ing MyD88, MyD88-adaptor-like (MAL, also known as
TIRAP), TIR-domain-containing adaptor protein inducing
IFNβ (TRIF; also known as TICAM1), TRIF-related adaptor
molecule (TRAM; also known as TICAM2), and sterile
α- and armadillo-motif-containing protein (SARM) [8–12].
Upon recognition of the cognate ligand, each TLR recruits a
speciﬁc adaptor molecule to activate diﬀerent transcription2 Gastroenterology Research and Practice
factors, giving rise to appropriate and eﬀective responses to
pathogens.
MyD88 is a universal adaptor molecule that activates
inﬂammatory pathways, and it is shared by all TLRs
with the exception of TLR3. The association of TLRs
and MyD88 stimulates the recruitment of members of the
IRAK family, including IRAK1, IRAK2, IRAK4, and IRAK-
M. In particular, IRAK4 is indispensable for activation of
the MyD88-dependent pathway [13]. Once phosphorylated,
IRAKs dissociate from MyD88 and interact with TRAF6,
which serves as a platform to recruit the kinase TAK1 [14].
Once activated, TAK1 activates MAP kinases (ERK, JNK,
p38) and the transcription factor NF-κB to control the
expression of inﬂammatory cytokine genes. TIRAP mediates
the activation of a MyD88-dependent pathway downstream
of TLR2 and TLR4. On the other hand, TLR3 activates
MyD88-independent signaling, indicating the importance
of other TIR domain-containing adaptor molecules that
function in the TLR3- and TLR4-mediated pathways [15].
TRIF plays a critical role in the TLR3- and TLR4-mediated
MyD88-independent pathways [10]. TRIF directly engages
with TLR3, whereas TRAM bridges the TLR4 interaction
[16]. TRIF cascade results in activation of IRF3. Phospho-
rylated IRF3 dimerizes and is translocated to the nucleus to
induce expression of type I IFN and IFN-inducible genes.
Brieﬂy, activation of TLR signaling culminates in NF-κBa n d
MAPKsthatregulategeneexpressionofvariousimmuneand
inﬂammatory mediators.
2. The Involvement of TLRs in
Inﬂammation-TriggeredHCC
TLRs are not only crucial to the initiation of the innate
and adaptive immune reactions, but also play a key role in
chronic inﬂammation. Aberrant activation of TLR pathways
has been implicated in a variety of chronic and autoim-
mune diseases [17–19]. Also, inﬂammation is an important
trigger for carcinogenesis of several human cancers. The
causal relationship of chronic inﬂammation with cancer
development was ﬁrst mentioned by Rudolph Virchow in
1863, who observed that tumors frequently developed on
sites of sustained inﬂammation and tumoral tissues were
often inﬁltrated by a variety of inﬂammatory cells [20].
Hepatocellular carcinoma (HCC) is a typical example of
inﬂammation-related cancer, which slowly unfolds on a
background of chronic inﬂammation mainly triggered by
exposure to infectious agents (chronic hepatitis B and C viral
infection) and toxic compounds (ethanol).
Many diﬀerent cell types in the liver express TLRs [21].
Hepatocytesuptakeandeliminateendotoxinfromportaland
systemic circulation. Primary cultured hepatocytes express
mRNA for all TLRs and respond to TLR2 and TLR4 ligands
[22]. Kupﬀer cells, hepatic resident macrophages, are located
in hepatic sinusoids and are the principal liver cells for
phagocytosis, antigen presentation, and the production of
inﬂammatory cytokines. Because of the unique anatomical
link between the liver and intestines, Kupﬀer cells are
the ﬁrst cells to encounter gut-derived toxins including
LPS, but are less responsive by “LPS tolerance” under the
physiological environment. Upon triggering, TLR4 signaling
drives Kupﬀer cells to produce a variety of inﬂammation-
relatedcytokines[23].KupﬀercellsalsoexpressTLR2,TLR3,
and TLR9 [24]. Hepatic stellate cells (HSCs) are located in
the space of Disse. Activated HSCs transdiﬀerentiate into
myoﬁboblasts, which then produce excessive ECM proteins,
including collagen type I, III, and IV. This leads to an
irreversible collagen deposition, resulting in liver ﬁbrosis.
HSCs express TLR4 and TLR9 [25, 26]. Biliary epithelial
cells may contact enteric bacteria by the anatomical linking
between the biliary system and the intestinal lumen. Biliary
epithelial cells express TLR2, TLR3, TLR4, and TLR5 [27].
Hepatic sinusoids are lined by liver sinusoidal endothelial
cells that express TLR4 [28].
Aberrant TLRs expressions have been noted in chronic
liverdiseasesofdiﬀerentetiology.InchronichepatitisBvirus
(HBV) infection, the injection of ligands for TLR3, TLR4,
TLR5, TLR7, and TLR9 suppresses HBV replication in an
IFN-α/β-dependent manner in HBV transgenic mice [29].
Further experiments demonstrated that nonparenchymal
liver cell-derived mediators inhibit HBV replication in HBV-
Met cells [30]. These data indicate that the innate immune
system of the liver can control HBV replication after
activation by TLR agonists. Hepatitis C virus (HCV) evades
the host immune system to sustain a chronic infection.
Chronic HCV infection causes chronic liver inﬂammation
and ﬁbrosis, resulting in cirrhosis and HCC. TLR2 and
TLR4 are markedly upregulated in hepatocytes, Kupﬀer cells,
and peripheral monocytes of patients with chronic hepatitis
C. TLR2-mediated activation by hepatitis C is linked to
the proinﬂammatory cytokine induction [31]. The HCV
core and NS3 protein activate TLR2/TLR1 and TLR2/TLR6
on monocytes to produce inﬂammatory cytokines [21].
Excessive alcohol intake changes the intestinal epithelial
barrier causing increased intestinal permeability followed by
elevated LPS levels in the portal circulation. The LPS then
activates TLR4 on Kupﬀer cells to produce proinﬂammatory
cytokines, such as TNF-α, leading to hepatocyte damage
[32]. In addition, Kupﬀer cells produce reactive oxygen
species (ROS) in response to chronic alcohol exposure as
well as endotoxin. Evidence shows that direct interaction
of NADPH oxidase isozyme 4 with TLR4 is involved in
LPS-mediated ROS generation and NFκBa c t i v a t i o ni n
neutrophils [33].
3.Adipokine: AKey Role in
Obesity-RelatedInﬂammation
Since obesity has become an epidemic health issue,
researchers have found that obesity, particularly abdominal
obesity, is associated with resistance to the eﬀects of insulin
on peripheral glucose and fatty acid utilization, often leading
to type 2 diabetes mellitus. Moreover, long-term status of
insulin resistance may cause vascular endothelial dysfunc-
tion, an abnormal lipid proﬁle, hypertension, and vascular
inﬂammation, all of which predispose to the development
of atherosclerotic cardiovascular disease (CVD). Therefore,Gastroenterology Research and Practice 3
“metabolic syndrome” is deﬁned to describe the strong
associationofobesitywiththesemetabolicdisorders.Indeed,
accumulating evidence has described a clear connection
between low-grade inﬂammatory responses and the devel-
opment of metabolic diseases, particularly in the context of
obesity and type 2 diabetes [34, 35]. Further investigations
show that obese persons have increased levels of C-reactive
protein (CRP), one proinﬂammatory marker in the blood
[36]. In addition, increased levels of CRP, and its inducer
interleukin-6 (IL-6), are predictive of the development of
type 2 diabetes in various populations [37].
Adipose tissue was traditionally considered to be a long-
term energy storage organ, but it is now appreciated that
it has a key role in the integration of systemic metabolism
[38]. This metabolic function is mediated, in a large part,
by its ability to secrete numerous proteins. Factors that are
secreted by adipose tissue have been collectively referred to
as adipokines. Adipokines have both proinﬂammatory and
anti-inﬂammatory activities, and the balance between these
factors is crucial for determining homeostasis throughout
the body based on nutritional status. When adipocyte
dysfunction occurs as a result of adipose tissue expansion
(whichmaybe duetoovernutrition orphysicalinactivity, for
example), dysregulation of adipokine production can have
local or systemic eﬀects on inﬂammatory responses, thereby
contributing to the initiation and progression of obesity-
induced metabolic and cardiovascular complications [39].
3.1. Leptin. Leptin is the product of the obese (ob)g e n e ,
was ﬁrst identiﬁed in ob/ob mice in 1994 [40]. Leptin is an
adipocyte-derived hormone/cytokine that links nutritional
statuswithneuroendocrineandimmunefunctions.Asahor-
mone, leptin regulates feeding behaviour through the central
nervous system. Mice that lack leptin (ob/ob mice) show
hyperphagia (abnormally increased feeding), obesity and
insulin resistance, and the administration of leptin to ob/ob
mice reverses these changes [41]. As a cytokine, leptin can
aﬀect thymic homeostasis and the secretion of acute-phase
reactants such as IL-1 and TNF, suggesting its modulating
role between immunity and inﬂammation. Leptin belongs to
the family of long-chain helical cytokines (characterized by a
four α-helix bundle) [42]. Leptin has structural similarity to
IL-6, IL-12, IL-15, granulocyte colony-stimulating factor (G-
CSF), and prolactin and growth hormone and is thought to
have proinﬂammatory activities. Indeed, leptin increases the
production of TNF and IL-6 by monocytes and stimulates
the production of CC-chemokine ligands (namely, CCL3,
CCL4, and CCL5) by macrophages by activating the JAK2
(Janus kinase 2)—STAT3 (signal transducer and activator
of transcription 3) pathway [43, 44]. In monocytes, leptin
also stimulates the production of ROs and promotes cell
proliferation and migratory responses [45]. Leptin levels in
the serum and adipose tissues are increased in response to
proinﬂammatory stimuli, including TNF and lipopolysac-
charide (LPS) [46].
3.2. Adiponectin. Adiponectin is mainly synthesized by
adipocytes and is present at high levels (3 to 30μg/mL)
in the blood [47]. Adiponectin is characterized by an
amino-terminalcollagen-likeregionandacarboxy-terminal,
complement factor C1q-like globular domain. Serum levels
of adiponectin are markedly decreased in individuals with
visceralobesityandstatesofinsulinresistance,suchasnonal-
coholic fatty liver disease, atherosclerosis and type 2 diabetes
mellitus, and adiponectin levels correlate inversely with
insulin resistance [48]. Much evidence from experimental
models indicates that adiponectin protects against obesity-
linkedmetabolicdysfunction.Administrationofadiponectin
to diabetic mice has been shown to reduce hyperglycaemia
by enhancing insulin activity and, when given to obese
mice, it increases fatty acid oxidation in muscle tissue and
reduces plasma levels of glucose, free fatty acids, and triglyc-
erides [49]. Early studies indicated that adiponectin had an
anti-inﬂammatory eﬀect on endothelial cells through the
inhibition of TNF-induced adhesion-molecule expression
[50]. Consistent with this, the production of adiponectin by
adipocytes is inhibited by proinﬂammatory factors, such as
TNF and IL-6, as well as by hypoxia and oxidative stress
[51]. Also, adiponectin has a crucial role in suppressing
macrophage activity, not only in adipose tissue but also
in other tissues such as the liver. Adiponectin can induce
the production of important anti-inﬂammatory cytokines,
such as IL-10 and IL-1 receptor antagonist (IL-1RA), by
human monocytes, macrophages, and dendritic cells and
can also suppress the production of interferon-γ by LPS-
stimulated humanmacrophages[52]. Recentevidence shows
that globular adiponectin suppresses TLR-induced NF-κB
activation, indicating that adiponectin negatively regulates
macrophage responses to TLR ligands, which is probably of
relevance in innate immune responses [53].
3.3. Resistin. (Also Known as FIZZ3) Resistin is a 114-
amino-acid polypeptide, was originally shown to induce
insulin resistance in mice [54] .I ti sam e m b e ro ft h e
cysteine-rich family of resistin-like molecules (RELMs) that
are associated with the activation of inﬂammatory processes
[55]. In mice, resistin protein synthesis is restricted to
adipocytes, whereas in humans, resistin is mainly produced
by macrophages and monocytes, and it is not detectable
in adipocytes [54, 56]. The proinﬂammatory properties of
resistin in human mononuclear cells are evident, as resistin
promotes the expression of TNF and IL-6 by these cells [57].
In addition, resistin directly counters the anti-inﬂammatory
eﬀects of adiponectin on vascular endothelial cells by
promoting the expression of the proinﬂammatory adhesion
molecules vascular cell adhesion molecule 1 (vCAm1),
intercellular adhesion molecule 1 (ICAm1), and pentraxin 3
in these cells, thereby enhancing leukocyte adhesion [58, 59].
3.4. Visfatin. (Also Known as PBEF) Visfatin has recently
been identiﬁed as an adipokine that is secreted by adipocytes
in visceral fat and that decreases insulin resistance [60]. This
molecule binds to and activates the insulin receptor but
does not compete with insulin, which indicates that the two
proteins bind diﬀerent sites on the insulin receptor. Visfatin
hasbeenlinkedtoseveralinﬂammatorydiseasestatessuchas4 Gastroenterology Research and Practice
acute lung injury [61]. Moreover, expression of visfatin has
been shown to be upregulated in activated neutrophils and
to inhibit the apoptosis of neutrophils [62].
3.5. TNF. TNF is a proinﬂammatory cytokine that is mainly
produced by monocytes and macrophages. TNF expression
was found to be increased in the adipose tissues of experi-
mental animal models of obesity and type 2 diabetes [63].
Further work demonstrated that TNF attenuated insulin-
stimulated tyrosine phosphorylation of the insulin receptor
and IRs1 in muscle and adipose tissues, thus promoting
insulin resistance [64]. These data support the notion that
TNF functions as a proinﬂammatory cytokine that has a
crucial role in obesity-related insulin resistance. In fact,
clinical data also showed that TNF levels were increased in
the adipose tissue and plasma of obese individuals, and a
reduction of body weight in these individuals was associated
with a decrease in TNF expression [65, 66].
3.6. IL-6. IL-6, a proinﬂammatory cytokine, is also involved
in obesity-related insulin resistance. It is estimated that
approximately one-third of total circulating IL-6 is pro-
duced by adipose tissues, and it is possible that increased
secretion of IL-6 under conditions of obesity contributes
to metabolic dysfunction [67]. Clinical data indicated the
positive correlation of plasma IL-6 levels with adiposity in
human populations. Furthermore, plasma levels IL-6 levels
wereincreasedinpatientswithtype2diabetes,andincreased
IL-6 levels were predictive of the development of type 2
diabetes [37].
4. The Interaction of Adipokines and
Toll-Like Receptors:A Linkbetween
Inﬂammationand Metabolism
In adipose tissue, adipocytes are the main cellular com-
ponents, and play a crucial role in both energy stor-
age and endocrine activity. Other active cell components
include macrophages and T cells, which have major roles
in determining the immune status of adipose tissue. As
obesity develops, adipocytes undergo hypertrophy owing
to increased triglyceride storage. Once qualitative changes
occur in the expanding adipose tissue, adipocytes will be
transformed to a metabolically dysfunctional phenotype. In
this state, adipose tissue generates large amounts of proin-
ﬂammatory adipokines, which will lead to the recruitment
and modulation of macrophages and other immune cells.
Therefore, obesity has recently been characterized by low
grade and chronic inﬂammation and is further deﬁned as
metaﬂammation [68].
Evidence has advocated that adipocytes may play a mod-
ulator role between inﬂammation and metabolic disorders
via TLR signaling cascades. Lin et al. were successful in
cloning Toll-like receptor-2 (TLR2) from 3T3-L1 adipocytes,
and they showed that adipocytic TLR2 synthesis increases
uponstimulationwithLPSandtumornecrosisfactor(TNF),
respectively [69]. Mesenchymal stem cells that were isolated
from human adipose tissue were reported to express TLR1 to
TLR6 and TLR9 [70]. Stimulation with bacterial LPS, yeast
cell wall zymosan, or TNF leads to a dramatic induction
of TLR2 synthesis [71]. Collectively, it is assumable that
adipokines might modulate obesity-related inﬂammatory
responses through TLR signaling.
Given the fact that leptin plays a regulatory role in
the immune system [72], recent study demonstrated the
expression and responsiveness of TLR1 to -9 in murine
preadipocytes as well as adipocytes, both of which are
strongly regulated by leptin [73]. In addition, ob/ob mice
(leptin-deﬁcient obese mice) and db/db mice (mice lacking
the long and functional isoform of the leptin receptor)
show the broadest mRNA expression proﬁle of TLRs in
preadipocytes and mature adipocytes. Recent data showed
that the obesity induced by leptin deﬁciency upregulated
the expression of TLR1-9 and TLR11-13 in murine adipose
tissues. These upregulated expressions of TLRs in the
expanded adipose tissues of obese animals were linked with
downstream NFκB, IRFs, and STAT-1 activation and upreg-
ulated cytokines and chemokines expression via MyD88-
dependent and -independent cascades in the adipose tissues
of the obese mice [74].
Accumulated evidence has indicated the anti-inﬂamm-
atory role of adiponectin. Plasma adiponectin levels are
negatively correlated with CRP levels in obese or diabetic
patients, and low adiponectin levels are associated with
higher CRP levels in nondiabetic or healthy subjects [75].
Adiponectin-deﬁcient mice have higher levels of Tnf mRNA
in adipose tissue and TNF protein in the blood, and these
increases were restored to normal levels on administration
of adiponectin [76]. In 2000, it was ﬁrst mentioned that
adiponectin could negatively regulate the functions of the
macrophages [77]. Further study showed that globular
adiponectin (gAcrp) could inhibit TLR-mediated NF-κB
signaling in mouse macrophage through binding to the
AdipoR1receptor[53].Inaddition,Huangetal.mentioneda
complex integrated mechanism that macrophage responded
to gAcrp [78]. gAcrp initially activated signaling path-
ways considered to be proinﬂammatory, with a subsequent
increase in the expression of the potent, anti-inﬂammatory
cytokine, and IL-10. Increased IL-10 expression was ulti-
mately required for the suppression of TLR4-mediated
signaling by gAcrp.
5. Obesity: A Newly EstablishedRisk for HCC
Hepatitis B carrier state, chronic hepatitis C virus infection
and alcoholism have been established as the main risk factors
of HCC for decades. However, it is estimated that 5% to 30%
of patients with HCC still lack a readily identiﬁable risk fac-
tor [79]. In 2004, Caldwell et al. emphasized the importance
of obesity in the occurrence of HCC [80]. Meanwhile, they
also mentioned that the intimate relationship between type
2 diabetes and HCC should not be neglected. Since then,
accumulatedstudies have attemptedto delineate howobesity
and its subsequent metabolic disease status contribute to the
development of HCC.
In recent years, the prevalence of obesity has progres-
sively increased worldwide and has become a major healthGastroenterology Research and Practice 5
issue. The World Health Organization estimates that by
2015, approximately 700 million adults will be obese [81].
Obesity is a medical condition in which excess body fat has
accumulated to the extent that it may cause a number of
health problems and lead to reduced life expectancy. Obesity
is associated with a broad range of comorbidities, also
includingcancer[82].Oneepidemiologicalreportpointsout
that 15–20% of all cancer deaths in the United States can be
attributed to overweight and obesity [83]. Furthermore, it is
foundthattherelativeriskofdyingfromlivercancerwas1.68
times higher among women with a baseline BMI ≥ 35kg/m2
and was 4.52 times higher for men with a similarly increased
BMI compared with the reference groups with baseline BMIs
of18.5 to 24.9kg/m2.Todate,nonalcoholic fattyliverdisease
(NAFLD) and diabetes are the most common obesity-related
comorbiditieswhichmayexplainthemajorityofcryptogenic
HCC without known underlying chronic liver disease [84,
85].
5.1. NAFLD and HCC. When the mechanisms linking obe-
sity to the development of HCC are discussed, nonalcoholic
fatty liver disease (NAFLD) might be the possible direction.
NAFLDencompassesaclinicopathologicspectrumofdisease
ranging from isolated hepatic steatosis to nonalcoholic
steatohepatitis (NASH), the more aggressive form of fatty
liver disease, which can progress to cirrhosis and its associ-
ated complications, including hepatic failure and HCC [86].
NASH may account for a large proportion of idiopathic or
cryptogenic cirrhosis (CC), which predisposes these patients
to the development of HCC [87].
The development of NASH is associated with oxidative
stress and the release of reactive oxygen species (ROS). An
insulin resistant obese mouse model demonstrated that ROS
production is increased in the mitochondria of hepatocytes
with fatty inﬁltration, and that oxidative stress may be
implicated in hepatic hyperplasia, which is a predisposing
f a c t o rf o rc a n c e rd e v e l o p m e n t[ 88]. HCC development
in NASH may be partially mediated by increased release
of inﬂammatory and inhibitory cytokines such as TNF-α,
IL-6, and NF-κB. Evidence suggests a complex molecular
interplay related to these inﬂammatory cytokines that leads
to hepatocyte death, compensatory proliferation, and ulti-
mately carcinogenesis [89]. A recent study by Luedde et
al. demonstrated that inhibition of NF-κB in mouse livers
induced steatohepatitis and ultimately HCC by sensitizing
hepatocytes to spontaneous apoptosis [90].
The c-Jun amino-terminal kinase 1 (JNK1) has also
recently been linked to obesity, insulin resistance, NASH,
and HCC development. JNK1 is a ubiquitously expressed,
mitogen-activated protein kinase. Obesity is associated with
abnormally elevated JNK activity. Free fatty acids, TNF-α,
and ROS released in the setting of hyperinsulinemia are
all potent activators of JNK [91]. More recently, deﬁnitive
evidence has revealed a signiﬁcant relationship between
sustained JNK activation and the development of HCC [92].
In one study, 56% of HCC tissue samples demonstrated
elevated JNK1 activity relative to the case-matched non-
cancerous liver tissue [93]. This sustained overactivation of
JNK1leadstoanaberrantincreaseinseveralgenesimportant
for hepatocyte proliferation [94].
5.2. Diabetes Mellitus and HCC. Large population-based
cohort studies from Sweden, Denmark, and Greece demon-
strate a 1.86- to 4-fold increase in risk of HCC among
patients with diabetes [95–97]. The risk of HCC with
diabetes remained elevated even after excluding patients who
were subsequently diagnosed with HCV, HBV, alcohol use,
and/or fatty liver disease at any time during the followup
[98]. Interestingly, the risk of HCC from diabetes may be
decreased with the use of statins. A total of 1303 cases and
5212 controls were compared in a nested, matched, case-
control study in patients with diabetes given the known
higher risk of developing HCC. The study demonstrated a
risk reduction range between 25% and 40% for the devel-
opment of HCC in diabetic patients who were prescribed
statins [99]. Therefore, diabetes is clearly established as an
independent risk factor for HCC.
6. The Involvementof Adipokines in
LiverCarcinogenesis
Since NAFLD, the hepatic presentation of the metabolic
syndrome has been established as another risk factor to
explain the majority of “cryptogenic” HCC, the association
of adipokines with HCC development has been widely
studied [100]. In 2006, Wang et al., who evaluated the
expression of leptin and its receptor in HCC specimens by
immunostaining, further correlated the expression proﬁle
withKi-67expression,intratumorMVD,andoverallsurvival
and provided clinical evidence on the prognostic roles of
leptin and OBR in HCC patients [101, 102]. First, OBR
expression was inversely correlated with vascular invasion
of HCC. Furthermore, high leptin expression was associated
with better survival in patients with HCC and treated post-
operatively with medroxyprogesterone acetate, a synthetic
variant of human progesterone. As a result, it was suggested
that both high leptin and OBR expression in HCC tissues
could predict better overall survival. A number of studies
havedeﬁnedtheeﬀectsofleptinonHCCprogression.Ribatti
et al., using the CAM assay, demonstrated the involvement of
leptin/leptin receptor in angiogenesis and tumor progression
of HCC [103]. Similar result in one in vitro assay suggested
that leptin-mediated neovascularization coordinated with
VEGF plays an important role in the development of liver
ﬁbrosis and hepatocarcinogenesis in NASH [104]. In addi-
tion, recent study further demonstrated that leptin promotes
hepatocytic cell cycle progression by upregulation of cyclin
D1 and reduces programmed cell death by downregulation
of Bax through a JAK2-PI3K/Akt-MEK/ERK1/2 cascaded
pathway [105].
Adiponectin interacts with at least two known cellular
receptors (AdipoR1 and AdipoR2). AdipoR1 is expressed
widely in mice, whereas AdipoR2 is expressed mainly in
the liver [106]. Activation of AdipoR1 and/or AdipoR2
by adiponectin stimulates the activation of peroxisome-
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protein kinase (AMPK), and p38 mitogen-activated protein
kinase. Adiponectin regulates the expression of several pro-
and anti-inﬂammatory cytokines. Recent in vitro assay
demonstrated that adiponectin could increase apoptosis of
HCC cells through increased phosphorylation of c-Jun-N-
terminal kinase (JNK) and subsequent activation of caspase-
3[ 107]. Moreover, analysis of adiponectin expression levels
in tissue microarray of human HCC patients revealed an
inverse correlation of adiponectin expression with tumor
size. Another study provided some important information
about the suppression of adiponectin on the oncogenic
actions of leptin in HCC [108]: (1) Adiponectin treatment
reduced leptin-induced Stat3 and Akt phosphorylation and
increased suppressor of cytokine signaling (SOCS3), a
physiologic negative regulator of leptin signal transduction.
(2) Adiponectin signiﬁcantly reduced leptin-induced tumor
burden in nude mice.
7. EvidenceIndicatingthe Potential
InterplaybetweenAdipokines and
TLRs inHCCDevelopment
As previously mentioned, TRLs have been implicated in the
HCC carcinogenesis initiated by chronic inﬂammation of
diﬀerent etiologies, including HBV, HCV, and alcohol [31].
Obesity, a state of chronic inﬂammation, has been newly
established as a potential promoter of HCC development, so
the adipokines become the potential candidates to explain
the link [84, 85]. In addition to the metabolic role, each
adipokine also individually exerts its proinﬂammatory or
anti-inﬂammatory eﬀect in a number of obesity-related
human disease, including HCC. In the context, both of
TLRs and adipokines function as the crucial link between
chronic inﬂammation and HCC; it is assumable that there
is some interplay between TLRs and adipokines in the hep-
atocarcinogenesis. Herein, previous evidence could provide
several clues to explain this potential interaction. First, TLRs
have been demonstrated to be expressed in diﬀerent types
of hepatic tissues (such as hepatocytes, Kupﬀer cells, and
stellate cells) [21], and accumulating data have unveiled the
eﬀects of diverse adipokines in these hepatic tissues [100,
107,108].Second,TLRsandadipokinereceptorshaveseveral
common intracellular targets (e.g., NF-κB and mitogen-
activated protein kinases), so it will not be surprising to ﬁnd
out some interaction between these two receptor families in
the future. Third, a number of adipokines (e.g., TNF and IL-
6), which are released by obese adipose tissue during weight
gain, greatly contribute to the recruitment of macrophages,
which have been demonstrated to express a range of TLRs.
Lastly, recent studies have reported that a variety of TLRs are
expressedintheadipocytes,andseveraladipokinesmodulate
the inﬂammation through TLR pathways.
8. Conclusions andFutureDirections
Adipose tissue has recently been considered as an endocrine
organ, because adipocytes can produce a variety of bioac-
tive hormones, collectively referred to as “adipokines”.
Adipokines are thought to provide an important link
betweenobesity,insulinresistance,andrelatedinﬂammatory
disorders. In addition to adipocytes, adipose tissues also
contain endothelial cells, ﬁbroblasts, leukocytes, and, most
importantly, macrophages. Once macrophages are present
and active in the adipose tissue during weight gain, they,
together with adipokines, might perpetuate a vicious cycle
ofmacrophagerecruitmentandproductionofproinﬂamma-
tory cytokines. Therefore, obesity has been considered as a
state of chronic low-grade inﬂammation.
TLRs, one type of pattern recognition receptor, can
be engaged by both exogenous ligands (derived from
pathogens) and endogenous ligands (products of cellular
injury) and consequently lead to the expression of diverse
inﬂammatory genes. It has been demonstrated that TLRs
are expressed on all major subsets of liver cells, including
hepatocytes, Kupﬀer cells, hepatic stellate cells, and so on.
Thesereceptorshavebeenimplicatedinchronicliverinﬂam-
mation of diﬀerent etiologies (HBV, HCV, toxic liver injury,
etc.), all of which might predispose to the development of
livercirrhosisandHCC.Recently,obesityhasbeenadvocated
as another new risk factor for HCC and could explain the
majority of “cryptogenic” HCC. In fact, TLRs have been
also considered as a key link between inﬂammation and
metabolism.
Accumulating data have been demonstrating their
respective contribution of adipokines and TLRs to the
carcinogenesis of HCC. In context of similar potential in
linking inﬂammation to metabolism, it is assumable that the
interplay between adipokines and TLRs might exert some
substantial eﬀects on the development of HCC. Also, a better
understandingintheinterplaybetweenadipokinesandTLRs
will shed light in a new therapeutic alternative in HCC.
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